Importantly, PROM2 was significantly upregulated in eight freshly collected pancreatic cancer tissues before gemcitabine-based treatment compared to two adjacent pancreatic tissues N1–N2 (Fig. 1d and Supplementary Fig. S1b). This evidence concerns the gene PROM2 and familial pancreatic carcinoma.